Fluticosone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluticosone

Quick Facts

Property Description
Active ingredient Fluticasone Propionate (INN)
Form Nasal suspension, Inhalation powder, Topical cream
Pharmacological class Glucocorticoid (Corticosteroid)
General purpose Anti-inflammatory and anti-swelling
Origin Synthetic fluorinated steroid

What Type of Medicine is Fluticasone Propionate?

Fluticasone Propionate is a potent, synthetic glucocorticoid classified pharmacologically as a corticosteroid, primarily serving as a powerful anti-inflammatory agent designed for localized action. The drug entity is a specialized fluorinated steroid chemically derived from natural hormones like Cortisol. This synthetic compound is highly effective and belongs to a class of compounds known for their anti-inflammatory and immunosuppressive effect. Fluticasone Propionate possesses a high binding affinity to the glucocorticoid receptor, supporting its designation as a high-potency topical agent.


Fluticasone Propionate: Composition and Physical Forms

The active ingredient, Fluticasone Propionate, is formulated as a propionate ester to ensure stability and potency, and is typically available as a locally-acting single active ingredient product. This active compound is delivered via different high-level forms appropriate for targeted application, including aqueous suspension or solution (for nasal spray), inhalation powder/suspension (for oral respiratory use), or as a topical cream/ointment. The propionate ester structure gives Fluticasone high lipophilicity, a distinguishing feature that allows for efficient local tissue penetration. This characteristic differentiates it from less fat-soluble corticosteroids, optimizing its performance in conditions like localized skin inflammation.


What is the General Purpose of This Glucocorticoid?

The general purpose of this long-acting medicine is to provide fundamental relief by directly and potently suppressing the immune response that drives chronic inflammation and swelling. Fluticasone achieves this anti-inflammatory effect by binding to specific glucocorticoid receptors within cells, thereby inhibiting the release of numerous inflammatory mediators responsible for irritation and tissue damage. This action, coupled with a potent vasoconstrictor property, results in a sustained reduction of localized tissue edema (swelling), helping to normalize tissue function rather than simply mitigating surface symptoms.

Regulatory References

  1. Fluticasone Propionate (MedlinePlus Drug Information)
  2. WHO Essential Medicines List Fluticasone

What side effects are possible with Fluticosone?

Possible Side Effects and Safety Information

The safety profile for Fluticasone Propionate, as established by regulatory documents, is structured around adverse reactions categorized by frequency and the body system affected. The most frequently observed side effects are often local, varying by formulation. For example, common reactions across formulations include headache, while nasal forms frequently list epistaxis (nosebleeds) and local irritation.


System-Organ Classes and Frequency

Adverse events are grouped by System-Organ Class (SOC) in regulatory labeling. The Infections and Infestations class includes common issues like oral or nasal candidiasis (thrush) [NIH]. Effects on the Respiratory System include common events like throat irritation and uncommon effects such as nasal ulceration or, in post-marketing reports, nasal septal perforation.

Classification Examples of Documented Reactions
Common Headache, Epistaxis, Throat Irritation, Oral Candidiasis
Rare/Very Rare Adrenal Suppression, Glaucoma, Cataracts

Serious Adverse Reactions and Special Safety Considerations

The profile also defines rare, serious systemic risks, particularly those related to its corticosteroid nature. Adrenal suppression (HPA axis suppression) and ocular complications, such as the development of glaucoma or cataracts, are documented as Very Rare but clinically significant adverse reactions [FDA Labeling (Section 5.5)].

Specific safety considerations exist for certain populations. Regulatory documents note the potential risk of growth retardation in children and adolescents, requiring regular monitoring of height [FDA Labeling (Section 5.7)]. Furthermore, patients with severe hepatic impairment may experience heightened systemic exposure, increasing the risk of systemic corticosteroid adverse effects [SmPC]. Prolonged use or high doses are officially stated to increase the likelihood of these systemic effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scenario

While an acute, single overdose of fluticasone delivered via inhalation is generally considered unlikely to cause serious issues due to its low systemic absorption, it is still crucial to monitor the situation. Most health authorities advise that an acute high-dose exposure typically requires only observation, and specialized treatment may not be necessary.

The principal risk associated with overexposure is from chronic use of excessively high doses over a prolonged period. This chronic overdose can lead to signs of systemic corticosteroid excess, specifically hypercorticism (Cushingoid features) and adrenal suppression (adrenocortical insufficiency). These effects are linked to the body's internal hormone regulation systems.

Emergency Actions

If you believe an overdose has occurred, or if someone has accidentally swallowed the medication, you should immediately seek emergency medical attention or contact a Poison Help line. It is especially critical to call emergency services if the individual collapses, has a seizure, or is not breathing. In cases of chronic overdose resulting in systemic effects, a healthcare provider will manage the situation by slowly discontinuing the product to allow the adrenal system to recover.

Key Symptoms of Chronic Overexposure

Signs of hypercorticism or adrenal suppression may include: unusual weakness or tiredness, loss of appetite, fainting, and potential changes in mental state or mood. Individuals with specific pre-existing conditions or those on interacting medications may be at a higher risk for these systemic effects.

Therapeutic Uses of Fluticosone

What Fluticasone Treats: Main Uses and Benefits

Fluticasone is commonly used across therapeutic areas where patients experience symptoms related to inflammatory or irritative states. This includes managing symptoms associated with both allergic and nonallergic inflammatory conditions.

This medication is applied across domains where additional symptomatic support is needed, relevant in conditions presenting with systemic or localized discomfort, such as those involving recurrent or episodic manifestations like asthma, rhinitis, or dermatitis.

“Fluticasone provides supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load.”

It is relevant for easing symptom clusters that may become disruptive, such as symptoms that create noticeable physiological strain, including wheezing, coughing, chest tightness, nasal congestion, and pruritic skin flare-ups. This is often used during phases when symptoms become more noticeable, and provides supportive relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Symptom Management Summary

Symptom Domain General Benefit
Symptoms related to heightened physiological activity Contributes to easing the overall symptom load.
Symptoms linked to organ-specific functional stress Supports improved day-to-day comfort during symptomatic periods.
Symptoms related to inflammatory or irritative states Provides supportive relief when symptoms become more disruptive during flare-ups.

Regulatory References

  1. NIH MedlinePlus overview on Fluticasone Nasal Spray

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Fluticasone — Official Regulatory Information


Eligibility Scope

Populations for whom use is allowed (as stated in label) Adults, adolescents, and pediatric patients who meet the minimum age threshold for the specific product (e.g., nasal spray ge 2 or ge 4 years).
Populations for whom use is not recommended (if applicable) Pregnant or lactating women, unless the benefit justifies the risk; children under the minimum approved age.
Populations for whom use is contraindicated Patients with known hypersensitivity to any ingredient; patients in status asthmaticus (inhaled forms); infants under 1 year (topical forms).
Age-related eligibility rules Minimum age varies by formulation (e.g., 2 to 16 years). Safety and efficacy are not established below these thresholds.
Condition-specific eligibility rules Use requires caution in patients with active infections (e.g., tuberculosis); avoidance in those with recent nasal trauma or ulcers; monitoring for severe hepatic impairment.
Pregnancy and lactation eligibility status (if explicitly documented) Use is conditional; permitted only if the potential benefit justifies the potential risk.
Eligibility-related restrictions Use with caution in patients transferring from systemic steroids or those with glaucoma/cataracts.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents) Contraindicated, Use with Caution/Avoidance, Not Recommended.
Regulatory basis (EMA / FDA / etc.) FDA Drug Labeling, EMA SmPC, MHRA.
Eligibility-context constraints (as defined in official documents) Formulation type, Infection status, Age group.

Resulting Eligibility Structure

Official eligibility statements:

  • Use is contraindicated in patients with known hypersensitivity to the drug or its components.
  • Eligibility is restricted by a minimum age threshold, which varies by product (e.g., ge 2 to ge 4 years for some nasal sprays).
  • Use requires caution in patients with certain untreated infections (e.g., tuberculosis) or those with recent nasal trauma.

Connection to the overall eligibility profile (4 sentences): Regulatory labeling explicitly defines who can and cannot use Fluticasone by establishing absolute prohibitions based on hypersensitivity and acute respiratory crisis. Furthermore, eligibility is restricted by minimum age requirements that differ across formulations and conditional limitations requiring caution due to existing infections or organ function status. For reproductive states, the decision-making process is limited by an official requirement that use must pass a potential benefit versus potential risk assessment. These statements collectively form the mandatory, label-based boundary for Fluticasone use.

What should I know about interactions with other medicines?

Fluticasone Interactions with other medicines and products

The official interaction profile for Fluticasone Propionate is defined by pharmacokinetic patterns related to its metabolic clearance. The substance is extensively metabolized by the enzyme Cytochrome P450 3A4 (CYP3A4).

This clearance pathway creates a risk of significant interaction with other medicines that are classified as strong CYP3A4 inhibitors. The most critical outcome is a substantial increase in Fluticasone systemic exposure (AUC and Cmax), which may lead to systemic corticosteroid effects, including the suppression of serum cortisol levels.

Formal Regulatory Restrictions

Interacting Substance Category Regulatory Requirement
Strong CYP3A4 Inhibitors Use not recommended due to potential for markedly increased systemic exposure.
Ritonavir / Ketoconazole Explicitly cited in regulatory documents as medicines to avoid co-administration with.

The combination of Fluticasone with specific strong inhibitors like Ritonavir is documented to cause a marked increase in plasma concentrations. Due to its dependence on hepatic clearance, the official profile includes a specific caution for patients with severe hepatic impairment. This population should be monitored closely for any signs of increased drug exposure, as their natural metabolic rate may be reduced. There are no mandatory administration timing rules, nor are there official interactions documented with food, alcohol, or common herbal products.

Mechanism of Action

Genomic Suppression of Inflammatory Signals

This core mechanism involves Fluticasone Propionate acting as an agonist at the intracellular Glucocorticoid Receptor (GR). By forming a complex that translocates to the nucleus, the drug directly engages in transrepression—switching off the genes for pro-inflammatory substances like cytokines and chemokines. This interaction regulates the cellular capacity for inflammatory signaling.


Comprehensive Modulation of Inflammatory Mediators

The drug’s action affects the synthesis and release of a broad spectrum of inflammatory mediators. This includes modulating the cascade that produces eicosanoids (prostaglandins and leukotrienes), resulting in the modulation of diverse inflammatory chemical signals. This mechanism reduces the production of chemokines that promote immune cell migration and decreases the release of signals responsible for inflammatory pathway continuation.


Localized Vascular Edema Control

Fluticasone also exerts a rapid, non-genomic influence on local tissue structures, inducing vasoconstriction. This targeted action on the microvasculature decreases the permeability of capillaries, thereby reducing the extravasation of fluid and cells into the tissue space. The immediate consequence of this mechanism is a reduction in localized tissue edema and hyperemia at the site of application.

Dosage and Administration Information

How to Use Fluticasone

Fluticasone is administered via the intranasal route for nasal formulations (sprays, drops) or the oral inhalation route for respiratory products (aerosols, powders).

Official Dosing and Frequency

Usage Population Recommended Starting Dose (Propionate) Frequency
Adults (Intranasal) 2 sprays (100 mu g) per nostril daily (200 mu g/day) Once Daily (or 1 spray twice daily)
Children 4-11 Years 1 spray (50 mu g) per nostril daily (100 mu g/day) Once Daily
Oral Inhalation Varies by strength, up to 500 mu g or more per dose Twice Daily

The maximum total daily dose should not be exceeded, and the prescribing principle dictates that the dosage must be titrated to the lowest effective level to maintain symptom control. For allergic rhinitis, treatment duration should generally not exceed the period of allergen exposure.


Administration Requirements

To ensure proper administration, the nasal spray device must be shaken gently and primed by spraying into the air before the first use or after a period of non-use. After using the oral inhalation product, patients are instructed to rinse their mouth with water and spit to clear residual drug from the mouth and throat.

Treatment must be taken at regular, scheduled intervals for its effectiveness, as the maximum therapeutic benefit may require several days of continuous use to be fully established. If a scheduled dose is missed, the regimen should be resumed with the next scheduled dose; doubling a dose is not permitted.

Recent Clinical Evidence

Fluticasone: Recent Clinical Evidence

Fluticasone is a synthetic corticosteroid compound indicated for use in managing inflammatory conditions, primarily affecting the respiratory tract (in nasal and inhalational forms) and skin (in topical forms). Based on its pharmacological properties, the compound functions as an anti-inflammatory agent.

Core Pharmacological Research

Research has explored the use of fluticasone in conditions such as seasonal and perennial allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD). The primary mechanism involves binding to glucocorticoid receptors, which is understood to modulate the expression of genes responsible for inflammatory responses.

Studies have examined the compound's effect on reducing local inflammation. Further research investigated whether this activity is associated with changes in symptoms like nasal congestion or airway hyper-responsiveness.


Clinical Trial Outcomes

Study Focus on Respiratory Symptoms (Short-Term)

Early clinical trials focused on acute symptom management across different formulations. Studies evaluated whether the compound is associated with a reduction in inflammation in the airways and nasal passages. Data from these initial phases generally investigated short-term changes in peak expiratory flow rates (PEFR) and symptom severity scores.

Comparative investigations have also explored the effects of fluticasone on symptom control when added to standard bronchodilator therapy, compared to using the bronchodilator alone. Findings were primarily focused on establishing the compound's tolerability and short-term symptom improvements.

Long-Term Investigations

Evidence on the long-term impact of fluticasone on disease modification remains under continuous study, particularly concerning potential effects on bone mineral density or adrenal function. While most studies have follow-up periods of less than one year, research continues to assess the overall safety profile for sustained use in chronic conditions.

Key Studies & References

  1. Efficacy of inhaled fluticasone propionate in adult asthma: a randomized controlled trial
  2. National Institute for Health and Care Excellence (NICE) Guideline: Asthma diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Fluticosone (FAQ)


Q: Does Fluticosone contain antihistamines?

No, Fluticasone is classified as a corticosteroid and is not an antihistamine. Regulatory documents confirm that the active ingredient is Fluticasone Propionate, which works to reduce inflammation. It does not contain an antihistamine component, which would function to block histamine release.


Q: Is Fluticosone the same as Flonase or Flovent?

Fluticasone is the official active ingredient found in several different products, including the branded medicines Flonase and Flovent. Specifically, Fluticasone Propionate is the active compound in Flonase nasal spray. Flovent is a distinct brand that contains fluticasone used for oral inhalation.


Q: Is Fluticosone only for allergies?

No, official regulatory documents indicate that Fluticasone is approved for a variety of inflammatory conditions. Depending on the specific formulation, approved uses include the management of symptoms for both allergic and nonallergic rhinitis. Other formulations are approved for respiratory conditions such as asthma and COPD.


Q: Can Fluticosone cause weight gain?

Regulatory information indicates that as a corticosteroid, Fluticasone has the potential for systemic effects if absorbed into the body. While rare, prolonged use or high systemic exposure in susceptible individuals may lead to conditions like hypercorticism. These serious systemic conditions are associated with documented changes in weight.


Q: Is it common for Fluticosone to make you feel tired?

Unusual weakness or fatigue is a documented adverse reaction, though it is not generally listed among the most common effects. Official product information notes that these symptoms may be a sign of rare, serious systemic effects, such as adrenal suppression (HPA axis suppression).


Q: Does Fluticosone affect sleep or cause insomnia?

The official product labeling for the single-ingredient formulation of Fluticasone does not specifically list insomnia as a side effect. However, regulatory warnings for some combined fluticasone products include mention of potential Central Nervous System (CNS) disorders. These types of warnings are included because CNS effects can potentially interfere with sleep patterns.


Q: What is the difference between Fluticasone Propionate and Fluticasone Furoate?

These are two chemically distinct forms of the same active drug, Fluticasone. The difference lies in their ester form, which can affect how they are absorbed and used by the body. These differences have resulted in separate regulatory approvals, often related to differences in recommended frequency of administration.


Q: Can Fluticosone interact with blood pressure medicine?

Regulatory documents warn that Fluticasone is metabolized by the CYP3A4 enzyme in the liver. This pathway creates a risk of interaction with certain other medicines, including some specific calcium channel blockers used for blood pressure, which are classified as CYP3A4 inhibitors. Such interactions may lead to higher levels of fluticasone in the body, which is a documented area of caution in the official profile.


Q: Is it possible to become dependent on Fluticosone?

Regulatory documents for this class of medicine (intranasal corticosteroids) do not list physical dependence or addiction as a risk. Fluticasone works differently from decongestant nasal sprays, which are known to cause rebound congestion upon stopping.


Q: Is Fluticosone available over the counter?

Yes, certain low-strength formulations of Fluticasone Propionate Nasal Spray are available for purchase over the counter (OTC) without a prescription. However, many other strengths and formulations of Fluticasone (such as those used for inhalation) remain available by prescription only.


Q: Can Fluticosone raise blood sugar levels?

As with many corticosteroids, regulatory information confirms that systemic absorption of Fluticasone may lead to elevated blood glucose levels, a condition known as hyperglycemia. The potential for this effect is why official guidance notes that caution is required for use in patients with diabetes mellitus or those prone to high blood sugar.


Q: Does Fluticosone help with post-nasal drip?

Fluticasone's mechanism of action is to reduce inflammation and swelling in the nasal passages. Approved indications, such as treating congestion and rhinitis symptoms, align with its use to manage the underlying swelling and irritation that often contributes to post-nasal drip.


Q: Is there a generic version of Fluticosone?

Yes. Fluticasone Propionate is widely available as a generic medication in various approved forms. The FDA approves generic versions after establishing that they are chemically equivalent to and can be substituted for their branded counterparts.


Q: Does Fluticosone contain oxy- or pseudoephedrine?

No. Fluticasone is classified as a corticosteroid and is not formulated with nasal decongestants like oxymetazoline or pseudoephedrine. Decongestants have a different mechanism of action and are regulated separately.


Q: Is it normal to feel a change in taste or smell when starting Fluticosone?

Yes, official regulatory adverse reaction tables list an unpleasant taste or unpleasant smell as a common side effect for some Fluticasone formulations. This is considered a localized reaction documented in regulatory adverse reaction tables.


Q: Are there specific warnings for seniors using Fluticosone?

Regulatory guidance for the geriatric population notes that elderly patients may be more likely to have age-related reductions in liver, kidney, or heart function. Because of this, official documents advise that caution may be necessary and note the potential need for careful assessment due to the possibility of age-related reductions in organ function.

How should Fluticosone be stored and disposed of?

How to Store and Dispose of Fluticasone

Fluticasone products must be stored at Controlled Room Temperature, typically between 20° to 25°C (68° to 77°F), and must be kept from freezing to maintain product integrity. The medication should remain in its original container, tightly closed, and protected from excess heat, moisture, and direct light.

All forms of Fluticasone must be stored out of the sight and reach of children as required by regulatory labeling. For disposal, unused or expired medication should be taken to a drug take-back program when available. Aerosol inhalers must not be punctured or thrown into a fire or incinerator, requiring contact with local waste authorities for proper environmental disposal according to local regulations. Specific inhalation devices must be discarded one month after first opening or after reaching the labeled number of actuations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluticosone found in:

A-Z Index: